Precision cancer drug rivoceranib has demonstrated excellent therapeutic effectiveness, with 85 percent of patients showing tumor cell disappearance and/or more than 30 percent reduction in tumor size in the neoadjuvant treatment of locally advanced esophageal squamous cell cancer (ESCC), according to results from a Phase 2 clinical trial recently published in BioMed Research International.
Please refer to the following website for further details: